These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 9080118

  • 1. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
    Clary BM, Coveney EC, Philip R, Blazer DG, Morse M, Gilboa E, Lyerly HK.
    Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
    Provinciali M, Argentati K, Tibaldi A.
    Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
    [Abstract] [Full Text] [Related]

  • 3. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.
    Clary BM, Coveney EC, Blazer DG, Philip R, Lyerly HK.
    Surgery; 1996 Aug; 120(2):174-81. PubMed ID: 8751580
    [Abstract] [Full Text] [Related]

  • 4. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [Abstract] [Full Text] [Related]

  • 5. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW, Li D, McQuone SJ, Ralston R.
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [Abstract] [Full Text] [Related]

  • 6. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
    Garbe AI, Vermeer B, Gamrekelashvili J, von Wasielewski R, Greten FR, Westendorf AM, Buer J, Schmid RM, Manns MP, Korangy F, Greten TF.
    Cancer Res; 2006 Jan 01; 66(1):508-16. PubMed ID: 16397267
    [Abstract] [Full Text] [Related]

  • 7. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O, Dohlsten M, Sjögren HO.
    Cancer Gene Ther; 2000 Oct 01; 7(10):1365-74. PubMed ID: 11059695
    [Abstract] [Full Text] [Related]

  • 8. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
    Abdel-Wahab Z, Dar M, Osanto S, Fong T, Vervaert CE, Hester D, Jolly D, Seigler HF.
    Cancer Gene Ther; 1997 Oct 01; 4(1):33-41. PubMed ID: 9012449
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer.
    Kim HS, Choo YS, Koo T, Bang S, Oh TY, Wen J, Song SY.
    Immunol Lett; 2006 Mar 15; 103(2):142-8. PubMed ID: 16313973
    [Abstract] [Full Text] [Related]

  • 10. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
    Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT.
    J Immunol; 1996 Jul 01; 157(1):231-8. PubMed ID: 8683120
    [Abstract] [Full Text] [Related]

  • 11. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
    Iwadate Y, Yamaura A, Sato Y, Sakiyama S, Tagawa M.
    Cancer Res; 2001 Dec 15; 61(24):8769-74. PubMed ID: 11751397
    [Abstract] [Full Text] [Related]

  • 12. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
    Iwadate Y, Yamaura A, Sakiyama S, Sato Y, Tagawa M.
    Int J Oncol; 2003 Aug 15; 23(2):483-8. PubMed ID: 12851699
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.
    Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B, Gilboa E.
    Cancer Res; 1994 Apr 01; 54(7):1760-5. PubMed ID: 8137291
    [Abstract] [Full Text] [Related]

  • 14. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
    Abdel-Wahab Z, Dar MM, Hester D, Vervaert C, Gangavalli R, Barber J, Darrow TL, Seigler HF.
    Cell Immunol; 1996 Aug 01; 171(2):246-54. PubMed ID: 8806794
    [Abstract] [Full Text] [Related]

  • 15. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH.
    Cancer Res; 2000 May 01; 60(9):2449-57. PubMed ID: 10811123
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
    Larchian WA, Horiguchi Y, Nair SK, Fair WR, Heston WD, Gilboa E.
    Clin Cancer Res; 2000 Jul 01; 6(7):2913-20. PubMed ID: 10914741
    [Abstract] [Full Text] [Related]

  • 17. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.
    Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP.
    Cancer Gene Ther; 2002 May 01; 9(5):464-9. PubMed ID: 11961669
    [Abstract] [Full Text] [Related]

  • 18. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
    Tahara H, Zeh HJ, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT.
    Cancer Res; 1994 Jan 01; 54(1):182-9. PubMed ID: 7903204
    [Abstract] [Full Text] [Related]

  • 19. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B.
    Cancer Gene Ther; 2000 Dec 01; 7(12):1543-56. PubMed ID: 11228533
    [Abstract] [Full Text] [Related]

  • 20. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.
    Mazzolini G, Narvaiza I, Martinez-Cruz LA, Arina A, Barajas M, Galofré JC, Qian C, Mato JM, Prieto J, Melero I.
    Gene Ther; 2003 Jul 01; 10(13):1067-78. PubMed ID: 12808437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.